Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis

BACKGROUND: Cabozantinib, a multiple kinase inhibitor, was recently approved for patients with previously treated unresectable hepatocellular carcinoma (uHCC). We investigated the real-world safety and efficacy profiles of cabozantinib. METHODS: This multicenter retrospective study included 110 pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Bang, Yeong Hak, Lee, Choong-kun, Yoo, Changhoon, Chon, Hong Jae, Hong, Moonki, Kang, Beodeul, Kim, Hyung-Don, Park, Sook Ryun, Choi, Won-Mook, Choi, Jonggi, Lee, Danbi, Shim, Ju Hyun, Kim, Kang Mo, Lim, Young-Suk, Lee, Han Chu, Ryu, Min-Hee, Ryoo, Baek-Yeol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118905/
https://www.ncbi.nlm.nih.gov/pubmed/35602405
http://dx.doi.org/10.1177/17588359221097934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118905/
https://www.ncbi.nlm.nih.gov/pubmed/35602405
http://dx.doi.org/10.1177/17588359221097934

Ejemplares similares